{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:44:24Z","timestamp":1790847864933,"version":"4.1.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>Buprenorphine mainly acts as an agonist of mu-opioid receptors (mu-OR). High dose buprenorphine does not cause respiratory depression and can be safely administered to elicit typical opioid effects and explore pharmacodynamics. Acute buprenorphine, associated with functional and quantitative neuroimaging, may therefore provide a fully translational pharmacological challenge to explore the variability of response to opioids <jats:italic>in vivo<\/jats:italic>. We hypothesized that the CNS effects of acute buprenorphine could be monitored through changes in regional brain glucose metabolism, assessed using <jats:sup>18<\/jats:sup>F-FDG microPET in rats.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>First, level of receptor occupancy associated with a single dose of buprenorphine (0.1\u2009mg\/kg, s.c) was investigated through blocking experiments using <jats:sup>11<\/jats:sup>C-buprenorphine PET imaging. Behavioral study using the elevated plus-maze test (EPM) was performed to assess the impact of the selected dose on anxiety and also locomotor activity. Then, brain PET imaging using <jats:sup>18<\/jats:sup>F-FDG was performed 30\u2009min after injection of unlabeled buprenorphine (0.1\u2009mg\/kg, s.c) vs. saline. Two different <jats:sup>18<\/jats:sup>F-FDG PET acquisition paradigms were compared: (i) <jats:sup>18<\/jats:sup>F-FDG injected i.v. under anesthesia and (ii) <jats:sup>18<\/jats:sup>F-FDG injected i.p. in awake animals to limit the impact of anesthesia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The selected dose of buprenorphine fully blocked the binding of <jats:sup>11<\/jats:sup>C-buprenorphine in brain regions, suggesting complete receptor occupancy. This dose had no significant impact on behavioral tests used, regardless of the anesthetized\/awake handling paradigm. In anesthetized rats, injection of unlabeled buprenorphine decreased the brain uptake of <jats:sup>18<\/jats:sup>F-FDG in most brain regions except in the cerebellum which could be used as a normalization region. Buprenorphine treatment significantly decreased the normalized brain uptake of <jats:sup>18<\/jats:sup>F-FDG in the thalamus, striatum and midbrain (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.05), where binding of <jats:sup>11<\/jats:sup>C-buprenorphine was the highest. The awake paradigm did not improve sensitivity and impact of buprenorphine on brain glucose metabolism could not be reliably estimated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Buprenorphine (0.1\u2009mg\/kg, s.c) combined with <jats:sup>18<\/jats:sup>F-FDG brain PET in isoflurane anesthetized rats provides a simple pharmacological imaging challenge to investigate the CNS effects of full receptor occupancy by this partial mu-OR agonist. Sensitivity of the method was not improved in awake animals. This strategy may be useful to investigate de desensitization of mu-OR associated with opioid tolerance <jats:italic>in vivo<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnins.2023.1181786","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T14:55:44Z","timestamp":1683730544000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Validation of a pharmacological imaging challenge using 11C-buprenorphine and 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography to study the effects of buprenorphine to the rat brain"],"prefix":"10.3389","volume":"17","author":[{"given":"Am\u00e9lie","family":"Soyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Leterrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Breuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Goislard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wadad","family":"Saba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Dal","family":"Bo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Bottlaender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Caill\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Goutal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Tournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1097\/CCM.0b013e318265680a","article-title":"Respiratory toxicity of buprenorphine results from the blockage of P-glycoprotein-mediated efflux of norbuprenorphine at the blood-brain barrier in mice","volume":"40","author":"Alhaddad","year":"2012","journal-title":"Crit. Care Med."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.nucmedbio.2020.08.001","article-title":"An original radio-biomimetic approach to synthesize radiometabolites for PET imaging","author":"Auvity","year":"2020","journal-title":"Nucl. Med. Biol."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1038\/s41386-021-00976-w","article-title":"Pharmacokinetic neuroimaging to study the dose-related brain kinetics and target engagement of buprenorphine in vivo","volume":"46","author":"Auvity","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1124\/jpet.112.201145","article-title":"Parallel buprenorphine phMRI responses in conscious rodents and healthy human subjects","volume":"345","author":"Becerra","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1124\/jpet.118.249839","article-title":"In vitro pharmacological characterization of buprenorphine, Samidorphan, and combinations being developed as an adjunctive treatment of major depressive disorder","volume":"367","author":"Bidlack","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.neuropharm.2018.12.012","article-title":"Locomotor and anti-immobility effects of buprenorphine in combination with the opioid receptor modulator samidorphan in rats","volume":"146","author":"Burke","year":"2019","journal-title":"Neuropharmacology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"6531","DOI":"10.1021\/jm2003238","article-title":"Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine","volume":"54","author":"Cami-Kobeci","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"861","DOI":"10.3389\/fneur.2018.00861","article-title":"Multimodal neuroimaging approach to variability of functional connectivity in disorders of consciousness: a PET\/MRI pilot study","volume":"9","author":"Cavaliere","year":"2018","journal-title":"Front. Neurol."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1152\/jn.01078.2015","article-title":"Novel method for functional brain imaging in awake minimally restrained rats","volume":"116","author":"Chang","year":"2016","journal-title":"J. Neurophysiol."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"E4190","DOI":"10.3390\/molecules24224190","article-title":"A survey of molecular imaging of opioid receptors","volume":"24","author":"Cumming","year":"2019","journal-title":"Molecules"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1093\/bja\/ael051","article-title":"Buprenorphine induces ceiling in respiratory depression but not in analgesia","volume":"96","author":"Dahan","year":"2006","journal-title":"Br. J. Anaesth."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1365-2125.2012.04317.x","article-title":"Differences between opioids: pharmacological, experimental, clinical and economical perspectives: differences between opioids","volume":"75","author":"Drewes","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"476","DOI":"10.2310\/7290.2015.00019","article-title":"[11C] Carfentanil binds preferentially to \u03bc-opioid receptor subtype 1 compared to subtype 2","volume":"14","author":"Eriksson","year":"2015","journal-title":"Mol. Imaging"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.neulet.2017.04.043","article-title":"The effects of methamphetamine and buprenorphine, and their interaction on anxiety-like behavior and locomotion in male rats","volume":"655","author":"Etaee","year":"2017","journal-title":"Neurosci. Lett."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jneumeth.2011.10.020","article-title":"A robust experimental protocol for pharmacological fMRI in rats and mice","volume":"204","author":"Ferrari","year":"2012","journal-title":"J. Neurosci. Methods"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/0969-8051(95)02087-X","article-title":"Opioid receptor imaging and displacement studies with [6-O-[11C] methyl] buprenorphine in baboon brain","volume":"23","author":"Galynker","year":"1996","journal-title":"Nucl. Med. Biol."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.annemergmed.2022.05.032","article-title":"A Neuropharmacological model to explain buprenorphine induction challenges","volume":"80","author":"Greenwald","year":"2022","journal-title":"Ann. Emerg. Med."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1038\/sj.npp.1300251","article-title":"Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers","volume":"28","author":"Greenwald","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.36076\/ppj.2008\/11\/225","article-title":"Opioid antagonists, partial agonists, and agonists\/antagonists: the role of office-based detoxification","volume":"11","author":"Helm","year":"2008","journal-title":"Pain Physician"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"835577","DOI":"10.3389\/fnins.2022.835577","article-title":"Impact of donepezil on brain glucose metabolism assessed using [18F]2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging in a mouse model of Alzheimer\u2019s disease induced by Intracerebroventricular injection of amyloid-Beta peptide","volume":"16","author":"Hugon","year":"2022","journal-title":"Front. Neurosci."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"816","DOI":"10.3390\/biom11060816","article-title":"Buprenorphine: far beyond the \u201cceiling\u201d","volume":"11","author":"Infantino","year":"2021","journal-title":"Biomol. Ther."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1742-7843.2011.00814.x","article-title":"Pharmacokinetic-pharmacodynamic modelling of opioids in healthy human volunteers. A minireview","volume":"110","author":"Ing Lorenzini","year":"2012","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.tips.2010.06.002","article-title":"Small-animal positron emission tomography as a tool for neuropharmacology","volume":"31","author":"Lancelot","year":"2010","journal-title":"Trends Pharmacol. Sci."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1021\/acschemneuro.8b00584","article-title":"Serotonin 5-HT1A receptor biased agonists induce different cerebral metabolic responses: a [18F]-Fluorodesoxyglucose positron emission tomography study in conscious and anesthetized rats","volume":"10","author":"Levigoureux","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2174\/1570159043359477","article-title":"Buprenorphine: a unique drug with complex pharmacology","volume":"2","author":"Lutfy","year":"2004","journal-title":"Curr. Neuropharmacol."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41386-018-0232-4","article-title":"Can neuroimaging help combat the opioid epidemic? A systematic review of clinical and pharmacological challenge fMRI studies with recommendations for future research","volume":"44","author":"Moningka","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1111\/j.1476-5381.2011.01335.x","article-title":"Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human","volume":"164","author":"Morgan","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/s0306-4522(98)00251-6","article-title":"Expression of mu, kappa, and delta opioid receptor messenger RNA in the human CNS: a 33P in situ hybridization study","volume":"88","author":"Peckys","year":"1999","journal-title":"Neuroscience"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"919773","DOI":"10.3389\/fnmol.2022.919773","article-title":"Opioid receptor-mediated regulation of neurotransmission in the brain","volume":"15","author":"Reeves","year":"2022","journal-title":"Front. Mol. Neurosci."},{"key":"ref30","first-page":"277","article-title":"Optimizing experimental protocols for quantitative behavioral imaging with 18F-FDG in rodents","volume":"48","author":"Schiffer","year":"2007","journal-title":"J. Nucl. Med."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e110432","DOI":"10.1371\/journal.pone.0110432","article-title":"Investigation of cross-species translatability of pharmacological MRI in awake nonhuman primate - a buprenorphine challenge study","volume":"9","author":"Seah","year":"2014","journal-title":"PLoS One"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13550-016-0242-3","article-title":"The effect of isoflurane on 18F-FDG uptake in the rat brain: a fully conscious dynamic PET study using motion compensation","volume":"6","author":"Spangler-Bickell","year":"2016","journal-title":"EJNMMI Res."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"4308","DOI":"10.1073\/pnas.84.12.4308","article-title":"Neuroanatomical patterns of the mu, delta, and kappa opioid receptors of rat brain as determined by quantitative in vitro autoradiography","volume":"84","author":"Tempel","year":"1987","journal-title":"Proc. Natl. Acad. Sci."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.neuroscience.2020.10.015","article-title":"Challenges and perspectives of the hybridization of PET with functional MRI or ultrasound for neuroimaging","volume":"474","author":"Tournier","year":"2021","journal-title":"Neuroscience"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"S133","DOI":"10.36076\/ppj.2008\/11\/S133","article-title":"Opioid pharmacology","volume":"11","author":"Trescot","year":"2008","journal-title":"Pain Physician"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1038\/npp.2011.156","article-title":"Imaging drugs with and without clinical analgesic efficacy","volume":"36","author":"Upadhyay","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.bja.2021.10.029","article-title":"Mechanisms of respiratory depression induced by the combination of buprenorphine and diazepam in rats","volume":"128","author":"Vodovar","year":"2022","journal-title":"Br. J. Anaesth."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41380-020-0661-4","article-title":"The changing opioid crisis: development, challenges and opportunities","volume":"26","author":"Volkow","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1056\/NEJMsr1706626","article-title":"The role of science in addressing the opioid crisis","volume":"377","author":"Volkow","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJMp1802741","article-title":"Primary care and the opioid-overdose crisis-buprenorphine myths and realities","volume":"379","author":"Wakeman","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/npp.1994.18","article-title":"Buprenorphine reduces cerebral glucose metabolism in polydrug abusers","volume":"10","author":"Walsh","year":"1994","journal-title":"Neuropsychopharmacology"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2165\/00003088-200746050-00005","article-title":"Animal-to-human extrapolation of the pharmacokinetic and Pharmacodynamic properties of buprenorphine","volume":"46","author":"Yassen","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1021\/acschemneuro.3c00036","article-title":"Positron emission tomography for the discovery of new drugs in psychiatry","volume":"14","author":"Zimmer","year":"2023","journal-title":"ACS Chem. Neurosci."}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2023.1181786\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T14:55:47Z","timestamp":1683730547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2023.1181786\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":43,"alternative-id":["10.3389\/fnins.2023.1181786"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2023.1181786","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,10]]},"article-number":"1181786"}}